The most compelling evidence for the utility of IGFBP7 and TGF-β with regard to DCM was presented by Shaver et al. [42], who investigated multiple serum biomarkers in a population from West Virginia. The gene discussed is TGFB1; the disease is familial dilated cardiomyopathy.